<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433482</url>
  </required_header>
  <id_info>
    <org_study_id>207467</org_study_id>
    <secondary_id>V59_78</secondary_id>
    <secondary_id>2017-003456-23</secondary_id>
    <nct_id>NCT03433482</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age</brief_title>
  <official_title>Immunogenicity, Reactogenicity and Safety Study of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) When Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MenACWY (Menveo) is a GSK vaccine intended for protection against disease caused by&#xD;
      meningococcal bacteria groups A, C, W and Y in infants, children and adults, licensed in more&#xD;
      than 60 countries.&#xD;
&#xD;
      The purpose of this study is to compare the immunogenicity of the currently licensed MenACWY&#xD;
      vaccine with the investigational MenACWY liquid vaccine aged for different lengths of time by&#xD;
      storage at 2-8ºC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Actual">December 17, 2019</completion_date>
  <primary_completion_date type="Actual">July 26, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Data will be collected in an observer-blind manner. By observer-blind, it is meant that during the course of the study, the vaccine recipient and those responsible for the evaluation of any study endpoint (e.g. safety, reactogenicity and immunogenicity) will all be unaware of which vaccine was administered. To do so, vaccine preparation and administration will be done by authorized medical personnel who will not participate in any of the study clinical evaluations.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup A for Each Vaccine Group and Between-group Ratios</measure>
    <time_frame>At Day 29</time_frame>
    <description>hSBA titers against N. meningitidis serogroup A are calculated in terms of GMTs adjusted for pre-vaccination titer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs Against Each of the N.Meningitidis Serogroups A,C,W and Y for Each Vaccine Group and Between-group Ratios</measure>
    <time_frame>At Day 1 and Day 29</time_frame>
    <description>hSBA titers were calculated in terms of GMTs, at Day 1 and Day 29, against each of the N. meningitidis serogroup A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-group Geometric Mean Ratios (GMRs) of GMTs Against Each of the N.Meningitidis Serogroups A,C,W and Y for Each Vaccine Group</measure>
    <time_frame>At Day 29</time_frame>
    <description>Within-group ratios of hSBA GMTs against each of the N.meningitidis serogroups A, C, W and Y at Day 29 compared to Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With ≥4 Fold Rise in hSBA Antibody Titers for Each of the N.Meningitidis Serogroups A, C,W and Y for Each Vaccine Group and Between-group Differences</measure>
    <time_frame>At Day 29</time_frame>
    <description>The percentages of subjects with a ≥ 4-fold rise in post-vaccination hSBA (at Day 29 compared to Day 1) and associated 2-sided 95% Clopper-Pearson CIs are computed by group and N. meningitidis serogroups A, C, W and Y. A 4-fold rise in the hSBA titers is defined as: - for individuals, whose pre-vaccination titers are &lt; the LOD (limit of detection), the post-vaccination titers must be ≥ 4-fold the LOD or ≥ the LLOQ (lower limit of quantitation) whichever is greater; - for individuals whose pre-vaccination titers are ≥ the LOD and ≤ the LLOQ, the post-vaccination titers must be at least four times the LLOQ; - for individuals whose pre-vaccination titers are &gt; the LLOQ, the post-vaccination titers must be at least four times the pre-vaccination titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Antibody Titers ≥8 Against Each of the N.Meningitidis Serogroups A,C,W and Y for Each Vaccine Group and Between-group Differences</measure>
    <time_frame>At Day 1 and Day 29</time_frame>
    <description>For each vaccine group the percentage of subjects with hSBA titer ≥8 , and its associated two-sided 95% Clopper-Pearson CIs are computed for each of the N. meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥LLOQ Against Each of the N. Meningitidis Serogroups A, C, W and Y for Each Vaccine Group, and Between-group Differences</measure>
    <time_frame>At Day 1 and Day 29</time_frame>
    <description>For each vaccine group the percentages of subjects with hSBA titer ≥LLOQ, and its associated two-sided 95% Clopper-Pearson CIs are computed for each of the N. meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reported With Any Unsolicited Adverse Events (AEs) Within 30 Minutes After Vaccination</measure>
    <time_frame>Within 30 minutes after vaccination at Day 1</time_frame>
    <description>An unsolicited adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reported With Solicited Local and Systemic AEs</measure>
    <time_frame>From Day 1 (6 hours) to Day 7 after vaccination</time_frame>
    <description>Assessed solicited local AEs were erythema, induration and pain at injection site. Assessed solicited systemic AEs were Arthralgia, chills, fatigue, fever (body temperature ≥38.0°C), headache, loss of appetite, myalgia and nausea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reported With Other Indicators of Reactogenicity</measure>
    <time_frame>From Day 1 to Day 7 after vaccination</time_frame>
    <description>Number of subjects reporting other indicators of reactogenicity such as use of analgesics/antipyretics within 7 days after any vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reported With Any Unsolicited AEs Within 29 Days After Vaccination</measure>
    <time_frame>From Day 1 to Day 29 after vaccination</time_frame>
    <description>An unsolicited adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reported With Serious Adverse Events (SAEs), AEs Leading to Withdrawal and Medically Attended AEs</measure>
    <time_frame>From Day 1 to Day 181 (during the entire study period)</time_frame>
    <description>Medically attended AEs are defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any medically attended AE(s) is occurrence of any medically attended AE(s) regardless of intensity grade or relation to vaccination. Serious adverse event is any congenital anomaly/birth defect in the offspring of a study subject or any untoward medical occurrence that results in death or life threatening or requires hospitalization or results in disability or incapacity</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1707</enrollment>
  <condition>Meningitis, Meningococcal</condition>
  <arm_group>
    <arm_group_label>GSK3536820A ACWY_Liq24 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACWY_1 Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK3536820A ACWY_Liq30 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACWY_2 Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY liquid</intervention_name>
    <description>At visit 1 (day 1), each subject will receive a single dose of the investigational MenACWY liquid vaccine (GSK3536820A) aged for approximately 24 months in Phase 1 of the study (subjects randomized to study arm ACWY_Liq24) or vaccine aged for 30 months in Phase 2 of the study (subjects randomized to study arm ACWY_Liq30), administered by intramuscular injection in the deltoid of the non-dominant arm.</description>
    <arm_group_label>GSK3536820A ACWY_Liq24 Group</arm_group_label>
    <arm_group_label>GSK3536820A ACWY_Liq30 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY</intervention_name>
    <description>At visit 1 (day 1), each subject will receive a single dose of the MenACWY vaccine in the Phase1 of the study (subjects randomized to study arm ACWY_1) or in phase 2 of the study (subjects randomized to study arm ACWY_2), administered by intramuscular injection in the deltoid of the non-dominant arm.</description>
    <arm_group_label>ACWY_1 Group</arm_group_label>
    <arm_group_label>ACWY_2 Group</arm_group_label>
    <other_name>Menveo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who, in the opinion of the investigator, can and will comply with the&#xD;
             requirements of the protocol or subjects' parent(s)/Legally Acceptable&#xD;
             Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will&#xD;
             comply, with the requirements of the protocol.&#xD;
&#xD;
          2. Written informed consent obtained from the subject/from the parent(s)/LAR(s) of the&#xD;
             subject prior to performing any study specific procedure.&#xD;
&#xD;
          3. Written informed assent obtained for subjects below legal age of consent, if required&#xD;
             by local regulations at the time of the enrolment.&#xD;
&#xD;
          4. A male or female ≥10 to ≤40 YoA at the time of the vaccination.&#xD;
&#xD;
          5. Healthy subjects as established by medical history and clinical examination before&#xD;
             entering into the study.&#xD;
&#xD;
          6. Female subjects of non-childbearing potential may be enrolled in the study.&#xD;
&#xD;
               -  Non-childbearing potential is defined as pre-menarche, current bilateral tubal&#xD;
                  ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause&#xD;
&#xD;
          7. Female subjects of childbearing potential may be enrolled in the study, if the&#xD;
             subject:&#xD;
&#xD;
               -  has practiced adequate contraception for 30 days prior to vaccination, and&#xD;
&#xD;
               -  has a negative pregnancy test on the day of vaccination, and&#xD;
&#xD;
               -  has agreed to continue adequate contraception during the entire treatment period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Child in care&#xD;
&#xD;
          2. Anaphylaxis following the administration of vaccine.&#xD;
&#xD;
          3. Any (clinical) condition that in the judgment of the investigator would make&#xD;
             intramuscular injection unsafe &amp;/represents a contraindication to intramuscular&#xD;
             vaccination and blood draws.&#xD;
&#xD;
          4. Any confirmed or suspected immunosuppressive or immunodeficient condition, including&#xD;
             HIV infection.&#xD;
&#xD;
          5. Progressive, unstable or uncontrolled clinical conditions.&#xD;
&#xD;
          6. Hypersensitivity, including allergy, to any component of vaccines, medicinal products&#xD;
             or medical equipment whose use is foreseen in this study.&#xD;
&#xD;
          7. Hypersensitivity to the active substances or to any of the excipients of the vaccine,&#xD;
             including diphtheria toxoid (CRM197), or a life-threatening reaction after previous&#xD;
             administration of a vaccine containing similar components.&#xD;
&#xD;
          8. Abnormal function of the immune system resulting from:&#xD;
&#xD;
               -  Clinical conditions.&#xD;
&#xD;
               -  Systemic administration of corticosteroids within 90 days prior to informed&#xD;
                  consent, and until the Day 29 blood draw.&#xD;
&#xD;
               -  Administration of antineoplastic and immunomodulating agents or radiotherapy&#xD;
                  within 90 days prior to informed consent, and until the Day 29 blood draw.&#xD;
&#xD;
          9. Received immunoglobulins or any blood products within 180 days prior to informed&#xD;
             consent.&#xD;
&#xD;
         10. Received an investigational or non-registered medicinal product within 30 days prior&#xD;
             to informed consent.&#xD;
&#xD;
         11. Any other clinical condition that, in the opinion of the investigator, might pose&#xD;
             additional risk to the subject due to participation in the study.&#xD;
&#xD;
         12. History of any meningococcal vaccination, with the exception of previous meningococcal&#xD;
             C vaccination, if the last dose of MenC was received at ≤24 months of age.&#xD;
&#xD;
         13. Individuals who received any other vaccines within 7 days (for inactivated vaccines)&#xD;
             or 14 days prior to enrolment in this study or who are planning to receive any vaccine&#xD;
             within 28 days from the study vaccines.*&#xD;
&#xD;
             * In case an emergency mass vaccination for an unforeseen public health threat is&#xD;
             organized by the public health authorities, outside the routine immunization program,&#xD;
             the time period described above can be reduced if necessary for that vaccine provided&#xD;
             it is licensed and used according to its Prescribing Information and according to the&#xD;
             local governmental recommendations and provided a written approval of the sponsor is&#xD;
             obtained.&#xD;
&#xD;
         14. Administration of long-acting immune-modifying drugs at any time during the study&#xD;
             period (e.g. infliximab).&#xD;
&#xD;
         15. Concurrently participating in another clinical study, at any time during the study&#xD;
             period, in which the subject has been or will be exposed to an investigational or a&#xD;
             non-investigational vaccine/product (pharmaceutical product or device).&#xD;
&#xD;
         16. Current or previous, confirmed or suspected disease caused by N. meningitidis.&#xD;
&#xD;
         17. Household contact with and/or intimate exposure to an individual with any laboratory&#xD;
             confirmed N. meningitidis infection within 60 days prior to study vaccination.&#xD;
&#xD;
         18. Acute disease and/or fever within 3 days prior to study vaccination. Note: enrolment&#xD;
             may be postponed/delayed until such transient circumstances have ended.&#xD;
&#xD;
               -  Fever is defined as body temperature ≥38.0°C/100.4°F. The preferred location for&#xD;
                  measuring temperature in this study will be the oral cavity.&#xD;
&#xD;
               -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory&#xD;
                  infection) without fever may be enrolled at the discretion of the investigator.&#xD;
&#xD;
         19. Received systemic antibiotic treatment within 3 days prior to study vaccination or&#xD;
             blood draw.&#xD;
&#xD;
         20. Study personnel as an immediate family or household member.&#xD;
&#xD;
         21. Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salvador</city>
        <state>Bahía</state>
        <zip>40420-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Do Norte</state>
        <zip>59025-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22271-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>01228-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10117</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>11313</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <zip>50106</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nantes cedex 2</city>
        <zip>44277</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nice</city>
        <zip>06300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosiers-d'Egletons</city>
        <zip>19300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Merida</city>
        <state>Yucatán</state>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durango</city>
        <zip>34000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gatchina</city>
        <zip>188300</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murmansk</city>
        <zip>183038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196240</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St.Petersburg</city>
        <zip>191025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St.Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634 050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150051</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0152</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bellville</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Centelles (Barcelona)</city>
        <zip>08540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Roca Del Valles (Barcelona)</city>
        <zip>08430</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quart De Poblet, Valencia</city>
        <zip>46930</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vic/ Barcelona</city>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eskisehir</city>
        <zip>26040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <results_first_submitted>January 27, 2021</results_first_submitted>
  <results_first_submitted_qc>January 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2021</results_first_posted>
  <disposition_first_submitted>June 19, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>June 19, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 2, 2020</disposition_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal disease</keyword>
  <keyword>Liquid formulation</keyword>
  <keyword>Meningitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis, Meningococcal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>https://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03433482/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03433482/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment was defined with 2 parallel groups per phase, in a 2-phase staggered design: Subjects in both experimental groups receiving investigational vaccine aged for approximately 24 months and 30 months in phase 1 and phase 2 respectively. Both comparator groups subjects in phase 1 and 2 of the study receiving licensed vaccine.</recruitment_details>
      <pre_assignment_details>Out of the 1707 subjects enrolled in the study (inclusive of phase 1 and 2), 1690 were exposed to the vaccination. Out of the 17 subjects excluded from study, 11 were not randomized, 5 were not administered any study treatment, 1 did not sign the informed consent form.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK3536820A ACWY_Liq24 Group</title>
          <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1</description>
        </group>
        <group group_id="P2">
          <title>ACWY_1 Group</title>
          <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.</description>
        </group>
        <group group_id="P3">
          <title>GSK3536820A ACWY_Liq30 Group</title>
          <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.</description>
        </group>
        <group group_id="P4">
          <title>ACWY_2 Group</title>
          <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="420"/>
                <participants group_id="P2" count="424"/>
                <participants group_id="P3" count="427"/>
                <participants group_id="P4" count="419"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="419"/>
                <participants group_id="P2" count="424"/>
                <participants group_id="P3" count="423"/>
                <participants group_id="P4" count="418"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK3536820A ACWY_Liq24 Group</title>
          <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1</description>
        </group>
        <group group_id="B2">
          <title>ACWY_1 Group</title>
          <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.</description>
        </group>
        <group group_id="B3">
          <title>GSK3536820A ACWY_Liq30 Group</title>
          <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.</description>
        </group>
        <group group_id="B4">
          <title>ACWY_2 Group</title>
          <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="420"/>
            <count group_id="B2" value="424"/>
            <count group_id="B3" value="427"/>
            <count group_id="B4" value="419"/>
            <count group_id="B5" value="1690"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.5" spread="9.4"/>
                    <measurement group_id="B2" value="22.2" spread="9.6"/>
                    <measurement group_id="B3" value="22.3" spread="9.8"/>
                    <measurement group_id="B4" value="22.0" spread="9.3"/>
                    <measurement group_id="B5" value="22.3" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="242"/>
                    <measurement group_id="B3" value="259"/>
                    <measurement group_id="B4" value="228"/>
                    <measurement group_id="B5" value="961"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="168"/>
                    <measurement group_id="B4" value="191"/>
                    <measurement group_id="B5" value="729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian Or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="84"/>
                    <measurement group_id="B5" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="332"/>
                    <measurement group_id="B2" value="343"/>
                    <measurement group_id="B3" value="311"/>
                    <measurement group_id="B4" value="304"/>
                    <measurement group_id="B5" value="1290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup A for Each Vaccine Group and Between-group Ratios</title>
        <description>hSBA titers against N. meningitidis serogroup A are calculated in terms of GMTs adjusted for pre-vaccination titer.</description>
        <time_frame>At Day 29</time_frame>
        <population>Analysis is performed on the per protocol set for immunogenicity that includes subjects who received the vaccine did not have any protocol deviation leading to exclusion , who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq24 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1</description>
          </group>
          <group group_id="O2">
            <title>ACWY_1 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.</description>
          </group>
          <group group_id="O3">
            <title>GSK3536820A ACWY_Liq30 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.</description>
          </group>
          <group group_id="O4">
            <title>ACWY_2 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup A for Each Vaccine Group and Between-group Ratios</title>
          <description>hSBA titers against N. meningitidis serogroup A are calculated in terms of GMTs adjusted for pre-vaccination titer.</description>
          <population>Analysis is performed on the per protocol set for immunogenicity that includes subjects who received the vaccine did not have any protocol deviation leading to exclusion , who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="373"/>
                <count group_id="O3" value="356"/>
                <count group_id="O4" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386.66" lower_limit="319.47" upper_limit="467.97"/>
                    <measurement group_id="O2" value="318.34" lower_limit="264.14" upper_limit="383.67"/>
                    <measurement group_id="O3" value="387.06" lower_limit="322.72" upper_limit="464.24"/>
                    <measurement group_id="O4" value="348.89" lower_limit="290.09" upper_limit="419.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate non-inferiority of the MenACWY liquid vaccine aged for approximately 24 months to that of currently licensed MenACWY vaccine, as measured by the adjusted hSBA GMTs directed against N. meningitidis serogroup A at Day 29 after a single dose vaccination</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is concluded if the lower limit of the two sided 95% confidence interval (CI) for the hSBA GMT ratio for serogroup A between the MenACWY liquid vaccine aged for approximately 24 months and the licensed MenACWY vaccine is &gt; 0.5.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>To demonstrate non-inferiority of the MenACWY liquid vaccine aged for approximately 30 months to that of currently licensed MenACWY vaccine, as measured by the adjusted hSBA GMTs directed against N. meningitidis serogroup A at Day 29 after a single dose vaccination.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is concluded if the lower limit of the two sided 95% CI for the hSBA GMT ratios for serogroup A between the MenACWY liquid vaccine aged for approximately 30 months and the licensed MenACWY vaccine is &gt; 0.5. Non-inferiority hypotheses testing will be conducted sequentially, starting from MenACWY liquid vaccine aged for approximately 24 months and subsequently with MenACWY liquid vaccine aged for approximately 30 months.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA GMTs Against Each of the N.Meningitidis Serogroups A,C,W and Y for Each Vaccine Group and Between-group Ratios</title>
        <description>hSBA titers were calculated in terms of GMTs, at Day 1 and Day 29, against each of the N. meningitidis serogroup A, C, W and Y.</description>
        <time_frame>At Day 1 and Day 29</time_frame>
        <population>Analysis is performed on the per protocol set for immunogenicity that includes subjects who received the vaccine did not have any protocol deviation leading to exclusion , who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq24 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1</description>
          </group>
          <group group_id="O2">
            <title>ACWY_1 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.</description>
          </group>
          <group group_id="O3">
            <title>GSK3536820A ACWY_Liq30 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.</description>
          </group>
          <group group_id="O4">
            <title>ACWY_2 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA GMTs Against Each of the N.Meningitidis Serogroups A,C,W and Y for Each Vaccine Group and Between-group Ratios</title>
          <description>hSBA titers were calculated in terms of GMTs, at Day 1 and Day 29, against each of the N. meningitidis serogroup A, C, W and Y.</description>
          <population>Analysis is performed on the per protocol set for immunogenicity that includes subjects who received the vaccine did not have any protocol deviation leading to exclusion , who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="395"/>
                <count group_id="O4" value="392"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis A, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="381"/>
                    <count group_id="O2" value="389"/>
                    <count group_id="O3" value="377"/>
                    <count group_id="O4" value="374"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" lower_limit="2.69" upper_limit="3.36"/>
                    <measurement group_id="O2" value="2.91" lower_limit="2.60" upper_limit="3.24"/>
                    <measurement group_id="O3" value="3.34" lower_limit="2.94" upper_limit="3.79"/>
                    <measurement group_id="O4" value="3.16" lower_limit="2.78" upper_limit="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="363"/>
                    <count group_id="O2" value="373"/>
                    <count group_id="O3" value="356"/>
                    <count group_id="O4" value="349"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="388.53" lower_limit="320.61" upper_limit="470.84"/>
                    <measurement group_id="O2" value="319.06" lower_limit="264.39" upper_limit="385.03"/>
                    <measurement group_id="O3" value="394.16" lower_limit="326.72" upper_limit="475.50"/>
                    <measurement group_id="O4" value="349" lower_limit="288.45" upper_limit="422.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="394"/>
                    <count group_id="O2" value="395"/>
                    <count group_id="O3" value="395"/>
                    <count group_id="O4" value="392"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.59" lower_limit="7.40" upper_limit="9.98"/>
                    <measurement group_id="O2" value="7.06" lower_limit="6.09" upper_limit="8.20"/>
                    <measurement group_id="O3" value="9.05" lower_limit="7.77" upper_limit="10.53"/>
                    <measurement group_id="O4" value="8.7" lower_limit="7.46" upper_limit="10.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="385"/>
                    <count group_id="O2" value="377"/>
                    <count group_id="O3" value="376"/>
                    <count group_id="O4" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.69" lower_limit="109.13" upper_limit="189.20"/>
                    <measurement group_id="O2" value="157.74" lower_limit="119.39" upper_limit="208.42"/>
                    <measurement group_id="O3" value="244.44" lower_limit="182.20" upper_limit="327.96"/>
                    <measurement group_id="O4" value="208.34" lower_limit="154.96" upper_limit="280.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="379"/>
                    <count group_id="O2" value="396"/>
                    <count group_id="O3" value="382"/>
                    <count group_id="O4" value="376"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.23" lower_limit="5.17" upper_limit="7.50"/>
                    <measurement group_id="O2" value="5.8" lower_limit="4.83" upper_limit="6.95"/>
                    <measurement group_id="O3" value="5.69" lower_limit="4.75" upper_limit="6.82"/>
                    <measurement group_id="O4" value="5.74" lower_limit="4.78" upper_limit="6.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="388"/>
                    <count group_id="O3" value="374"/>
                    <count group_id="O4" value="366"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.73" lower_limit="49.93" upper_limit="78.81"/>
                    <measurement group_id="O2" value="63.92" lower_limit="51.11" upper_limit="79.94"/>
                    <measurement group_id="O3" value="80.51" lower_limit="64.66" upper_limit="100.24"/>
                    <measurement group_id="O4" value="73.08" lower_limit="58.45" upper_limit="91.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="390"/>
                    <count group_id="O2" value="398"/>
                    <count group_id="O3" value="391"/>
                    <count group_id="O4" value="385"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" lower_limit="3.78" upper_limit="5.10"/>
                    <measurement group_id="O2" value="4.21" lower_limit="3.63" upper_limit="4.89"/>
                    <measurement group_id="O3" value="4.14" lower_limit="3.58" upper_limit="4.79"/>
                    <measurement group_id="O4" value="4.19" lower_limit="3.62" upper_limit="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="379"/>
                    <count group_id="O2" value="390"/>
                    <count group_id="O3" value="386"/>
                    <count group_id="O4" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.42" lower_limit="94.03" upper_limit="144.15"/>
                    <measurement group_id="O2" value="105.11" lower_limit="85.17" upper_limit="129.71"/>
                    <measurement group_id="O3" value="112.95" lower_limit="91.55" upper_limit="139.34"/>
                    <measurement group_id="O4" value="118.04" lower_limit="95.27" upper_limit="146.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-groups ratio of adjusted hSBA GMTs and its 95% CI, between vaccine groups GSK3536820A ACWY_Liq24 and ACWY_1, at Day 29 against serogroup C</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT ratio</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-groups ratio of adjusted hSBA GMTs and its 95% CI, between vaccine groups GSK3536820A ACWY_Liq24 and ACWY_1, at Day 29 against serogroup W</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-groups ratio of adjusted hSBA GMTs and its 95% CI, between vaccine groups GSK3536820A ACWY_Liq24 and ACWY_1, at Day 29 against serogroup Y</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT ratio</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-groups ratio of adjusted hSBA GMTs and its 95% CI, between vaccine groups GSK3536820A ACWY_Liq30 and ACWY_2, at Day 29 against serogroup C</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT ratio</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-groups ratio of adjusted hSBA GMTs and its 95% CI, between vaccine groups GSK3536820A ACWY_Liq30 and ACWY_2, at Day 29 against serogroup W</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-groups ratio of adjusted hSBA GMTs and its 95% CI, between vaccine groups GSK3536820A ACWY_Liq30 and ACWY_2, at Day 29 against serogroup Y</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-group Geometric Mean Ratios (GMRs) of GMTs Against Each of the N.Meningitidis Serogroups A,C,W and Y for Each Vaccine Group</title>
        <description>Within-group ratios of hSBA GMTs against each of the N.meningitidis serogroups A, C, W and Y at Day 29 compared to Day 1.</description>
        <time_frame>At Day 29</time_frame>
        <population>Analysis is performed on the per protocol set for immunogenicity that includes subjects who received the vaccine did not have any protocol deviation leading to exclusion , who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq24 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1</description>
          </group>
          <group group_id="O2">
            <title>ACWY_1 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.</description>
          </group>
          <group group_id="O3">
            <title>GSK3536820A ACWY_Liq30 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.</description>
          </group>
          <group group_id="O4">
            <title>ACWY_2 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Within-group Geometric Mean Ratios (GMRs) of GMTs Against Each of the N.Meningitidis Serogroups A,C,W and Y for Each Vaccine Group</title>
          <description>Within-group ratios of hSBA GMTs against each of the N.meningitidis serogroups A, C, W and Y at Day 29 compared to Day 1.</description>
          <population>Analysis is performed on the per protocol set for immunogenicity that includes subjects who received the vaccine did not have any protocol deviation leading to exclusion , who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="390"/>
                <count group_id="O3" value="386"/>
                <count group_id="O4" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="363"/>
                    <count group_id="O2" value="373"/>
                    <count group_id="O3" value="356"/>
                    <count group_id="O4" value="349"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.33" lower_limit="105.49" upper_limit="161.02"/>
                    <measurement group_id="O2" value="108.39" lower_limit="88.14" upper_limit="133.30"/>
                    <measurement group_id="O3" value="114.66" lower_limit="93.75" upper_limit="140.22"/>
                    <measurement group_id="O4" value="106.79" lower_limit="87.05" upper_limit="131.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="385"/>
                    <count group_id="O2" value="377"/>
                    <count group_id="O3" value="376"/>
                    <count group_id="O4" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.01" lower_limit="13.00" upper_limit="22.25"/>
                    <measurement group_id="O2" value="21.68" lower_limit="16.52" upper_limit="28.46"/>
                    <measurement group_id="O3" value="26.69" lower_limit="20.22" upper_limit="35.22"/>
                    <measurement group_id="O4" value="23.85" lower_limit="18.04" upper_limit="31.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="388"/>
                    <count group_id="O3" value="374"/>
                    <count group_id="O4" value="366"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.81" lower_limit="7.84" upper_limit="12.27"/>
                    <measurement group_id="O2" value="10.77" lower_limit="8.65" upper_limit="13.41"/>
                    <measurement group_id="O3" value="13.8" lower_limit="11.08" upper_limit="17.19"/>
                    <measurement group_id="O4" value="12.48" lower_limit="9.98" upper_limit="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="379"/>
                    <count group_id="O2" value="390"/>
                    <count group_id="O3" value="386"/>
                    <count group_id="O4" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.53" lower_limit="21.14" upper_limit="33.28"/>
                    <measurement group_id="O2" value="25.23" lower_limit="20.18" upper_limit="31.54"/>
                    <measurement group_id="O3" value="27.18" lower_limit="21.66" upper_limit="34.10"/>
                    <measurement group_id="O4" value="28.49" lower_limit="22.60" upper_limit="35.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With ≥4 Fold Rise in hSBA Antibody Titers for Each of the N.Meningitidis Serogroups A, C,W and Y for Each Vaccine Group and Between-group Differences</title>
        <description>The percentages of subjects with a ≥ 4-fold rise in post-vaccination hSBA (at Day 29 compared to Day 1) and associated 2-sided 95% Clopper-Pearson CIs are computed by group and N. meningitidis serogroups A, C, W and Y. A 4-fold rise in the hSBA titers is defined as: - for individuals, whose pre-vaccination titers are &lt; the LOD (limit of detection), the post-vaccination titers must be ≥ 4-fold the LOD or ≥ the LLOQ (lower limit of quantitation) whichever is greater; - for individuals whose pre-vaccination titers are ≥ the LOD and ≤ the LLOQ, the post-vaccination titers must be at least four times the LLOQ; - for individuals whose pre-vaccination titers are &gt; the LLOQ, the post-vaccination titers must be at least four times the pre-vaccination titer.</description>
        <time_frame>At Day 29</time_frame>
        <population>Analysis is performed on the per protocol set for immunogenicity that includes subjects who received the vaccine did not have any protocol deviation leading to exclusion , who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq24 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1</description>
          </group>
          <group group_id="O2">
            <title>ACWY_1 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.</description>
          </group>
          <group group_id="O3">
            <title>GSK3536820A ACWY_Liq30 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.</description>
          </group>
          <group group_id="O4">
            <title>ACWY_2 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With ≥4 Fold Rise in hSBA Antibody Titers for Each of the N.Meningitidis Serogroups A, C,W and Y for Each Vaccine Group and Between-group Differences</title>
          <description>The percentages of subjects with a ≥ 4-fold rise in post-vaccination hSBA (at Day 29 compared to Day 1) and associated 2-sided 95% Clopper-Pearson CIs are computed by group and N. meningitidis serogroups A, C, W and Y. A 4-fold rise in the hSBA titers is defined as: - for individuals, whose pre-vaccination titers are &lt; the LOD (limit of detection), the post-vaccination titers must be ≥ 4-fold the LOD or ≥ the LLOQ (lower limit of quantitation) whichever is greater; - for individuals whose pre-vaccination titers are ≥ the LOD and ≤ the LLOQ, the post-vaccination titers must be at least four times the LLOQ; - for individuals whose pre-vaccination titers are &gt; the LLOQ, the post-vaccination titers must be at least four times the pre-vaccination titer.</description>
          <population>Analysis is performed on the per protocol set for immunogenicity that includes subjects who received the vaccine did not have any protocol deviation leading to exclusion , who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="390"/>
                <count group_id="O3" value="386"/>
                <count group_id="O4" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="363"/>
                    <count group_id="O2" value="373"/>
                    <count group_id="O3" value="356"/>
                    <count group_id="O4" value="349"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.29" lower_limit="89.04" upper_limit="94.81"/>
                    <measurement group_id="O2" value="90.08" lower_limit="86.59" upper_limit="92.92"/>
                    <measurement group_id="O3" value="91.57" lower_limit="88.19" upper_limit="94.24"/>
                    <measurement group_id="O4" value="91.69" lower_limit="88.28" upper_limit="94.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="385"/>
                    <count group_id="O2" value="377"/>
                    <count group_id="O3" value="376"/>
                    <count group_id="O4" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.34" lower_limit="57.29" upper_limit="67.20"/>
                    <measurement group_id="O2" value="64.46" lower_limit="59.39" upper_limit="69.29"/>
                    <measurement group_id="O3" value="72.61" lower_limit="67.80" upper_limit="77.05"/>
                    <measurement group_id="O4" value="69.76" lower_limit="64.85" upper_limit="74.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="388"/>
                    <count group_id="O3" value="374"/>
                    <count group_id="O4" value="366"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.41" lower_limit="54.23" upper_limit="64.44"/>
                    <measurement group_id="O2" value="60.57" lower_limit="55.51" upper_limit="65.46"/>
                    <measurement group_id="O3" value="66.58" lower_limit="61.55" upper_limit="71.34"/>
                    <measurement group_id="O4" value="62.57" lower_limit="57.39" upper_limit="67.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="379"/>
                    <count group_id="O2" value="390"/>
                    <count group_id="O3" value="386"/>
                    <count group_id="O4" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.77" lower_limit="66.95" upper_limit="76.25"/>
                    <measurement group_id="O2" value="73.33" lower_limit="68.65" upper_limit="77.66"/>
                    <measurement group_id="O3" value="74.35" lower_limit="69.69" upper_limit="78.64"/>
                    <measurement group_id="O4" value="77.19" lower_limit="72.62" upper_limit="81.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentage of subjects with a ≥ 4-fold rise in post-vaccination hSBA for N. meningitidis serogroup A at Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>2.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.94</ci_lower_limit>
            <ci_upper_limit>6.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentage of subjects with a ≥ 4-fold rise in post-vaccination hSBA for N. meningitidis serogroup C at Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-2.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.94</ci_lower_limit>
            <ci_upper_limit>4.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentage of subjects with a ≥ 4-fold rise in post-vaccination hSBA for N. meningitidis serogroup W at Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.11</ci_lower_limit>
            <ci_upper_limit>5.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentage of subjects with a ≥ 4-fold rise in post-vaccination hSBA for N. meningitidis serogroup Y at Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.88</ci_lower_limit>
            <ci_upper_limit>4.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentage of subjects with a ≥ 4-fold rise in post-vaccination hSBA for N. meningitidis serogroup A at Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.29</ci_lower_limit>
            <ci_upper_limit>4.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentage of subjects with a ≥ 4-fold rise in post-vaccination hSBA for N. meningitidis serogroup C at Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>2.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.63</ci_lower_limit>
            <ci_upper_limit>9.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentage of subjects with a ≥ 4-fold rise in post-vaccination hSBA for N. meningitidis serogroup W at Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>4.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.89</ci_lower_limit>
            <ci_upper_limit>10.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentage of subjects with a ≥ 4-fold rise in post-vaccination hSBA for N. meningitidis serogroup Y at Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-2.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.91</ci_lower_limit>
            <ci_upper_limit>3.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Antibody Titers ≥8 Against Each of the N.Meningitidis Serogroups A,C,W and Y for Each Vaccine Group and Between-group Differences</title>
        <description>For each vaccine group the percentage of subjects with hSBA titer ≥8 , and its associated two-sided 95% Clopper-Pearson CIs are computed for each of the N. meningitidis serogroups A, C, W and Y.</description>
        <time_frame>At Day 1 and Day 29</time_frame>
        <population>Analysis is performed on the per protocol set for immunogenicity that includes subjects who received the vaccine did not have any protocol deviation leading to exclusion , who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq24 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1</description>
          </group>
          <group group_id="O2">
            <title>ACWY_1 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.</description>
          </group>
          <group group_id="O3">
            <title>GSK3536820A ACWY_Liq30 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.</description>
          </group>
          <group group_id="O4">
            <title>ACWY_2 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Antibody Titers ≥8 Against Each of the N.Meningitidis Serogroups A,C,W and Y for Each Vaccine Group and Between-group Differences</title>
          <description>For each vaccine group the percentage of subjects with hSBA titer ≥8 , and its associated two-sided 95% Clopper-Pearson CIs are computed for each of the N. meningitidis serogroups A, C, W and Y.</description>
          <population>Analysis is performed on the per protocol set for immunogenicity that includes subjects who received the vaccine did not have any protocol deviation leading to exclusion , who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="395"/>
                <count group_id="O4" value="392"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis A, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="381"/>
                    <count group_id="O2" value="389"/>
                    <count group_id="O3" value="377"/>
                    <count group_id="O4" value="374"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.07" lower_limit="8.98" upper_limit="15.77"/>
                    <measurement group_id="O2" value="10.28" lower_limit="7.45" upper_limit="13.74"/>
                    <measurement group_id="O3" value="13.53" lower_limit="10.24" upper_limit="17.40"/>
                    <measurement group_id="O4" value="12.03" lower_limit="8.91" upper_limit="15.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="378"/>
                    <count group_id="O2" value="384"/>
                    <count group_id="O3" value="377"/>
                    <count group_id="O4" value="367"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.65" lower_limit="90.70" upper_limit="95.89"/>
                    <measurement group_id="O2" value="92.19" lower_limit="89.03" upper_limit="94.67"/>
                    <measurement group_id="O3" value="93.37" lower_limit="90.37" upper_limit="95.66"/>
                    <measurement group_id="O4" value="94.01" lower_limit="91.06" upper_limit="96.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="394"/>
                    <count group_id="O2" value="395"/>
                    <count group_id="O3" value="395"/>
                    <count group_id="O4" value="392"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.48" lower_limit="43.44" upper_limit="53.53"/>
                    <measurement group_id="O2" value="41.52" lower_limit="36.61" upper_limit="46.55"/>
                    <measurement group_id="O3" value="50.63" lower_limit="45.59" upper_limit="55.67"/>
                    <measurement group_id="O4" value="50.26" lower_limit="45.19" upper_limit="55.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="388"/>
                    <count group_id="O2" value="382"/>
                    <count group_id="O3" value="379"/>
                    <count group_id="O4" value="379"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.58" lower_limit="73.10" upper_limit="81.63"/>
                    <measurement group_id="O2" value="78.01" lower_limit="73.52" upper_limit="82.06"/>
                    <measurement group_id="O3" value="84.17" lower_limit="80.10" upper_limit="87.70"/>
                    <measurement group_id="O4" value="82.85" lower_limit="78.67" upper_limit="86.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="379"/>
                    <count group_id="O2" value="396"/>
                    <count group_id="O3" value="382"/>
                    <count group_id="O4" value="376"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.66" lower_limit="27.01" upper_limit="36.61"/>
                    <measurement group_id="O2" value="28.54" lower_limit="24.14" upper_limit="33.26"/>
                    <measurement group_id="O3" value="28.8" lower_limit="24.30" upper_limit="33.62"/>
                    <measurement group_id="O4" value="30.05" lower_limit="25.46" upper_limit="34.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="389"/>
                    <count group_id="O2" value="392"/>
                    <count group_id="O3" value="389"/>
                    <count group_id="O4" value="384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.43" lower_limit="75.07" upper_limit="83.34"/>
                    <measurement group_id="O2" value="80.87" lower_limit="76.62" upper_limit="84.64"/>
                    <measurement group_id="O3" value="85.86" lower_limit="82.00" upper_limit="89.17"/>
                    <measurement group_id="O4" value="81.77" lower_limit="77.54" upper_limit="85.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="390"/>
                    <count group_id="O2" value="398"/>
                    <count group_id="O3" value="391"/>
                    <count group_id="O4" value="385"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.82" lower_limit="18.75" upper_limit="27.31"/>
                    <measurement group_id="O2" value="21.86" lower_limit="17.90" upper_limit="26.25"/>
                    <measurement group_id="O3" value="21.48" lower_limit="17.51" upper_limit="25.89"/>
                    <measurement group_id="O4" value="22.34" lower_limit="18.27" upper_limit="26.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="384"/>
                    <count group_id="O2" value="392"/>
                    <count group_id="O3" value="393"/>
                    <count group_id="O4" value="386"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="83.77" upper_limit="90.64"/>
                    <measurement group_id="O2" value="85.46" lower_limit="81.57" upper_limit="88.80"/>
                    <measurement group_id="O3" value="88.04" lower_limit="84.42" upper_limit="91.08"/>
                    <measurement group_id="O4" value="87.56" lower_limit="83.85" upper_limit="90.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup A on Day 1.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.69</ci_lower_limit>
            <ci_upper_limit>6.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup C on Day 1.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>6.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>13.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup W on Day 1.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>3.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.33</ci_lower_limit>
            <ci_upper_limit>9.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup Y on Day 1.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.86</ci_lower_limit>
            <ci_upper_limit>6.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup A on Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>1.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.24</ci_lower_limit>
            <ci_upper_limit>5.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup C on Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.32</ci_lower_limit>
            <ci_upper_limit>5.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup W on Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.05</ci_lower_limit>
            <ci_upper_limit>4.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup Y on Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>2.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.81</ci_lower_limit>
            <ci_upper_limit>6.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup A on Day 1.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.32</ci_lower_limit>
            <ci_upper_limit>6.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup C on Day 1.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.60</ci_lower_limit>
            <ci_upper_limit>7.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup W on Day 1.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.75</ci_lower_limit>
            <ci_upper_limit>5.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup Y on Day 1.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.69</ci_lower_limit>
            <ci_upper_limit>4.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup A on Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.24</ci_lower_limit>
            <ci_upper_limit>2.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup C on Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.99</ci_lower_limit>
            <ci_upper_limit>6.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 the N. meningitidis serogroup W on Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>4.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.11</ci_lower_limit>
            <ci_upper_limit>9.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup Y on Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.16</ci_lower_limit>
            <ci_upper_limit>5.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥LLOQ Against Each of the N. Meningitidis Serogroups A, C, W and Y for Each Vaccine Group, and Between-group Differences</title>
        <description>For each vaccine group the percentages of subjects with hSBA titer ≥LLOQ, and its associated two-sided 95% Clopper-Pearson CIs are computed for each of the N. meningitidis serogroups A, C, W and Y.</description>
        <time_frame>At Day 1 and Day 29</time_frame>
        <population>Analysis is performed on the per protocol set for immunogenicity that includes subjects who received the vaccine did not have any protocol deviation leading to exclusion , who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq24 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1</description>
          </group>
          <group group_id="O2">
            <title>ACWY_1 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.</description>
          </group>
          <group group_id="O3">
            <title>GSK3536820A ACWY_Liq30 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.</description>
          </group>
          <group group_id="O4">
            <title>ACWY_2 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥LLOQ Against Each of the N. Meningitidis Serogroups A, C, W and Y for Each Vaccine Group, and Between-group Differences</title>
          <description>For each vaccine group the percentages of subjects with hSBA titer ≥LLOQ, and its associated two-sided 95% Clopper-Pearson CIs are computed for each of the N. meningitidis serogroups A, C, W and Y.</description>
          <population>Analysis is performed on the per protocol set for immunogenicity that includes subjects who received the vaccine did not have any protocol deviation leading to exclusion , who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="395"/>
                <count group_id="O4" value="392"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis A, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="381"/>
                    <count group_id="O2" value="389"/>
                    <count group_id="O3" value="377"/>
                    <count group_id="O4" value="374"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.86" lower_limit="9.67" upper_limit="16.64"/>
                    <measurement group_id="O2" value="11.57" lower_limit="8.56" upper_limit="15.17"/>
                    <measurement group_id="O3" value="15.38" lower_limit="11.89" upper_limit="19.43"/>
                    <measurement group_id="O4" value="13.64" lower_limit="10.32" upper_limit="17.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="378"/>
                    <count group_id="O2" value="384"/>
                    <count group_id="O3" value="377"/>
                    <count group_id="O4" value="367"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.92" lower_limit="91.01" upper_limit="96.10"/>
                    <measurement group_id="O2" value="92.19" lower_limit="89.03" upper_limit="94.67"/>
                    <measurement group_id="O3" value="93.37" lower_limit="90.37" upper_limit="95.66"/>
                    <measurement group_id="O4" value="94.01" lower_limit="91.06" upper_limit="96.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="394"/>
                    <count group_id="O2" value="395"/>
                    <count group_id="O3" value="395"/>
                    <count group_id="O4" value="392"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.84" lower_limit="50.78" upper_limit="60.81"/>
                    <measurement group_id="O2" value="48.61" lower_limit="43.58" upper_limit="53.66"/>
                    <measurement group_id="O3" value="61.01" lower_limit="56.01" upper_limit="65.85"/>
                    <measurement group_id="O4" value="57.14" lower_limit="52.08" upper_limit="62.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="388"/>
                    <count group_id="O2" value="382"/>
                    <count group_id="O3" value="379"/>
                    <count group_id="O4" value="379"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.38" lower_limit="75.01" upper_limit="83.30"/>
                    <measurement group_id="O2" value="80.37" lower_limit="76.02" upper_limit="84.23"/>
                    <measurement group_id="O3" value="84.7" lower_limit="80.67" upper_limit="88.17"/>
                    <measurement group_id="O4" value="84.7" lower_limit="80.67" upper_limit="88.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="379"/>
                    <count group_id="O2" value="396"/>
                    <count group_id="O3" value="382"/>
                    <count group_id="O4" value="376"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.45" lower_limit="27.76" upper_limit="37.42"/>
                    <measurement group_id="O2" value="28.54" lower_limit="24.14" upper_limit="33.26"/>
                    <measurement group_id="O3" value="29.32" lower_limit="24.80" upper_limit="34.16"/>
                    <measurement group_id="O4" value="30.05" lower_limit="25.46" upper_limit="34.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="389"/>
                    <count group_id="O2" value="392"/>
                    <count group_id="O3" value="389"/>
                    <count group_id="O4" value="384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.43" lower_limit="75.07" upper_limit="83.34"/>
                    <measurement group_id="O2" value="80.87" lower_limit="76.62" upper_limit="84.64"/>
                    <measurement group_id="O3" value="85.86" lower_limit="82.00" upper_limit="89.17"/>
                    <measurement group_id="O4" value="81.77" lower_limit="77.54" upper_limit="85.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="390"/>
                    <count group_id="O2" value="398"/>
                    <count group_id="O3" value="391"/>
                    <count group_id="O4" value="385"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.36" lower_limit="20.18" upper_limit="28.93"/>
                    <measurement group_id="O2" value="22.86" lower_limit="18.83" upper_limit="27.31"/>
                    <measurement group_id="O3" value="21.74" lower_limit="17.75" upper_limit="26.16"/>
                    <measurement group_id="O4" value="22.86" lower_limit="18.76" upper_limit="27.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="384"/>
                    <count group_id="O2" value="392"/>
                    <count group_id="O3" value="393"/>
                    <count group_id="O4" value="386"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.28" lower_limit="84.63" upper_limit="91.32"/>
                    <measurement group_id="O2" value="86.22" lower_limit="82.41" upper_limit="89.48"/>
                    <measurement group_id="O3" value="88.3" lower_limit="84.70" upper_limit="91.30"/>
                    <measurement group_id="O4" value="87.56" lower_limit="83.85" upper_limit="90.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup A at Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.37</ci_lower_limit>
            <ci_upper_limit>5.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup C at Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>7.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>14.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup W at Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>3.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.57</ci_lower_limit>
            <ci_upper_limit>10.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup Y at Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.44</ci_lower_limit>
            <ci_upper_limit>7.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup A at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>1.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.94</ci_lower_limit>
            <ci_upper_limit>5.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup C at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.66</ci_lower_limit>
            <ci_upper_limit>4.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup W at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.05</ci_lower_limit>
            <ci_upper_limit>4.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup Y at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>2.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.67</ci_lower_limit>
            <ci_upper_limit>6.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup A at Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>1.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.32</ci_lower_limit>
            <ci_upper_limit>6.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup C at Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>3.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.00</ci_lower_limit>
            <ci_upper_limit>10.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup W at Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.24</ci_lower_limit>
            <ci_upper_limit>5.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup Y at Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.99</ci_lower_limit>
            <ci_upper_limit>4.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup A at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.24</ci_lower_limit>
            <ci_upper_limit>2.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup C at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.16</ci_lower_limit>
            <ci_upper_limit>5.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup W at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>4.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.11</ci_lower_limit>
            <ci_upper_limit>9.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup Y at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.88</ci_lower_limit>
            <ci_upper_limit>5.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reported With Any Unsolicited Adverse Events (AEs) Within 30 Minutes After Vaccination</title>
        <description>An unsolicited adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Within 30 minutes after vaccination at Day 1</time_frame>
        <population>Analysis was performed on the unsolicited safety set that includes all enrolled subjects who received a study vaccination and reported unsolicited adverse events data for the defined period.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq24 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1</description>
          </group>
          <group group_id="O2">
            <title>ACWY_1 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.</description>
          </group>
          <group group_id="O3">
            <title>GSK3536820A ACWY_Liq30 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.</description>
          </group>
          <group group_id="O4">
            <title>ACWY_2 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reported With Any Unsolicited Adverse Events (AEs) Within 30 Minutes After Vaccination</title>
          <description>An unsolicited adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.</description>
          <population>Analysis was performed on the unsolicited safety set that includes all enrolled subjects who received a study vaccination and reported unsolicited adverse events data for the defined period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
                <count group_id="O2" value="424"/>
                <count group_id="O3" value="427"/>
                <count group_id="O4" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reported With Solicited Local and Systemic AEs</title>
        <description>Assessed solicited local AEs were erythema, induration and pain at injection site. Assessed solicited systemic AEs were Arthralgia, chills, fatigue, fever (body temperature ≥38.0°C), headache, loss of appetite, myalgia and nausea.</description>
        <time_frame>From Day 1 (6 hours) to Day 7 after vaccination</time_frame>
        <population>Analysis was performed on the solicited safety set that includes all enrolled subjects who received a study vaccination and reported solicited adverse events data for the defined period.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq24 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1</description>
          </group>
          <group group_id="O2">
            <title>ACWY_1 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.</description>
          </group>
          <group group_id="O3">
            <title>GSK3536820A ACWY_Liq30 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.</description>
          </group>
          <group group_id="O4">
            <title>ACWY_2 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reported With Solicited Local and Systemic AEs</title>
          <description>Assessed solicited local AEs were erythema, induration and pain at injection site. Assessed solicited systemic AEs were Arthralgia, chills, fatigue, fever (body temperature ≥38.0°C), headache, loss of appetite, myalgia and nausea.</description>
          <population>Analysis was performed on the solicited safety set that includes all enrolled subjects who received a study vaccination and reported solicited adverse events data for the defined period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="422"/>
                <count group_id="O3" value="425"/>
                <count group_id="O4" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="175"/>
                    <measurement group_id="O3" value="149"/>
                    <measurement group_id="O4" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (Temperature &gt;= 38 C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="151"/>
                    <measurement group_id="O3" value="169"/>
                    <measurement group_id="O4" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189"/>
                    <measurement group_id="O2" value="181"/>
                    <measurement group_id="O3" value="202"/>
                    <measurement group_id="O4" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reported With Other Indicators of Reactogenicity</title>
        <description>Number of subjects reporting other indicators of reactogenicity such as use of analgesics/antipyretics within 7 days after any vaccination</description>
        <time_frame>From Day 1 to Day 7 after vaccination</time_frame>
        <population>Analysis was performed on the solicited safety set that includes all enrolled subjects who received a study vaccination and reported solicited adverse events data for the defined period.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq24 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1</description>
          </group>
          <group group_id="O2">
            <title>ACWY_1 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.</description>
          </group>
          <group group_id="O3">
            <title>GSK3536820A ACWY_Liq30 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.</description>
          </group>
          <group group_id="O4">
            <title>ACWY_2 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reported With Other Indicators of Reactogenicity</title>
          <description>Number of subjects reporting other indicators of reactogenicity such as use of analgesics/antipyretics within 7 days after any vaccination</description>
          <population>Analysis was performed on the solicited safety set that includes all enrolled subjects who received a study vaccination and reported solicited adverse events data for the defined period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="422"/>
                <count group_id="O3" value="425"/>
                <count group_id="O4" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Analgesic/Antipyretic Prevention, No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357"/>
                    <measurement group_id="O2" value="374"/>
                    <measurement group_id="O3" value="366"/>
                    <measurement group_id="O4" value="369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/Antipyretic Prevention, Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/Antipyretic Treatment, No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328"/>
                    <measurement group_id="O2" value="340"/>
                    <measurement group_id="O3" value="349"/>
                    <measurement group_id="O4" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/Antipyretic Treatment, Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reported With Any Unsolicited AEs Within 29 Days After Vaccination</title>
        <description>An unsolicited adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>From Day 1 to Day 29 after vaccination</time_frame>
        <population>Analysis was performed on the unsolicited safety set that includes all enrolled subjects who received a study vaccination and reported unsolicited adverse events data for the defined period.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq24 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1</description>
          </group>
          <group group_id="O2">
            <title>ACWY_1 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.</description>
          </group>
          <group group_id="O3">
            <title>GSK3536820A ACWY_Liq30 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.</description>
          </group>
          <group group_id="O4">
            <title>ACWY_2 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reported With Any Unsolicited AEs Within 29 Days After Vaccination</title>
          <description>An unsolicited adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.</description>
          <population>Analysis was performed on the unsolicited safety set that includes all enrolled subjects who received a study vaccination and reported unsolicited adverse events data for the defined period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
                <count group_id="O2" value="424"/>
                <count group_id="O3" value="427"/>
                <count group_id="O4" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="101"/>
                    <measurement group_id="O4" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reported With Serious Adverse Events (SAEs), AEs Leading to Withdrawal and Medically Attended AEs</title>
        <description>Medically attended AEs are defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any medically attended AE(s) is occurrence of any medically attended AE(s) regardless of intensity grade or relation to vaccination. Serious adverse event is any congenital anomaly/birth defect in the offspring of a study subject or any untoward medical occurrence that results in death or life threatening or requires hospitalization or results in disability or incapacity</description>
        <time_frame>From Day 1 to Day 181 (during the entire study period)</time_frame>
        <population>Analysis was performed on the unsolicited safety set that includes all enrolled subjects who received a study vaccination and reported unsolicited adverse events data for the defined period.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq24 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1</description>
          </group>
          <group group_id="O2">
            <title>ACWY_1 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.</description>
          </group>
          <group group_id="O3">
            <title>GSK3536820A ACWY_Liq30 Group</title>
            <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.</description>
          </group>
          <group group_id="O4">
            <title>ACWY_2 Group</title>
            <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reported With Serious Adverse Events (SAEs), AEs Leading to Withdrawal and Medically Attended AEs</title>
          <description>Medically attended AEs are defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any medically attended AE(s) is occurrence of any medically attended AE(s) regardless of intensity grade or relation to vaccination. Serious adverse event is any congenital anomaly/birth defect in the offspring of a study subject or any untoward medical occurrence that results in death or life threatening or requires hospitalization or results in disability or incapacity</description>
          <population>Analysis was performed on the unsolicited safety set that includes all enrolled subjects who received a study vaccination and reported unsolicited adverse events data for the defined period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
                <count group_id="O2" value="424"/>
                <count group_id="O3" value="427"/>
                <count group_id="O4" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs Leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited AEs were collected from Day 1 to Day 7 after vaccination and Unsolicited AEs from Day 1 to Day 29 after vaccination. SAEs were collected from Day 1 to Day 181 (during the entire study period)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GSK3536820A ACWY_Liq24 Group</title>
          <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1</description>
        </group>
        <group group_id="E2">
          <title>ACWY_1 Group</title>
          <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.</description>
        </group>
        <group group_id="E3">
          <title>GSK3536820A ACWY_Liq30 Group</title>
          <description>Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.</description>
        </group>
        <group group_id="E4">
          <title>ACWY_2 Group</title>
          <description>Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="427"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis noninfective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa uteri pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="312" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="314" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="324" subjects_at_risk="427"/>
                <counts group_id="E4" subjects_affected="317" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="420"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="424"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="427"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="427"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="56" subjects_affected="54" subjects_at_risk="420"/>
                <counts group_id="E2" events="49" subjects_affected="48" subjects_at_risk="424"/>
                <counts group_id="E3" events="45" subjects_affected="43" subjects_at_risk="427"/>
                <counts group_id="E4" events="46" subjects_affected="46" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Administration site induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Administration site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Application site warmth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="78" subjects_affected="77" subjects_at_risk="420"/>
                <counts group_id="E2" events="81" subjects_affected="79" subjects_at_risk="424"/>
                <counts group_id="E3" events="78" subjects_affected="78" subjects_at_risk="427"/>
                <counts group_id="E4" events="57" subjects_affected="56" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="175" subjects_affected="175" subjects_at_risk="420"/>
                <counts group_id="E2" events="179" subjects_affected="175" subjects_at_risk="424"/>
                <counts group_id="E3" events="157" subjects_affected="150" subjects_at_risk="427"/>
                <counts group_id="E4" events="150" subjects_affected="147" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="51" subjects_affected="50" subjects_at_risk="420"/>
                <counts group_id="E2" events="52" subjects_affected="51" subjects_at_risk="424"/>
                <counts group_id="E3" events="68" subjects_affected="59" subjects_at_risk="427"/>
                <counts group_id="E4" events="47" subjects_affected="42" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="53" subjects_affected="52" subjects_at_risk="420"/>
                <counts group_id="E2" events="51" subjects_affected="51" subjects_at_risk="424"/>
                <counts group_id="E3" events="62" subjects_affected="54" subjects_at_risk="427"/>
                <counts group_id="E4" events="43" subjects_affected="39" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Injection site oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="193" subjects_affected="190" subjects_at_risk="420"/>
                <counts group_id="E2" events="183" subjects_affected="182" subjects_at_risk="424"/>
                <counts group_id="E3" events="214" subjects_affected="205" subjects_at_risk="427"/>
                <counts group_id="E4" events="201" subjects_affected="194" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="420"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="424"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="427"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Injection site scab</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="427"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="420"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="424"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="427"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Vessel puncture site induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Balanitis candida</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Enterobiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="424"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="427"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Injection site cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="420"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="424"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="427"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="420"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="424"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="427"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="420"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="424"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="427"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="55" subjects_affected="54" subjects_at_risk="420"/>
                <counts group_id="E2" events="56" subjects_affected="54" subjects_at_risk="424"/>
                <counts group_id="E3" events="64" subjects_affected="63" subjects_at_risk="427"/>
                <counts group_id="E4" events="36" subjects_affected="34" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="50" subjects_at_risk="420"/>
                <counts group_id="E2" events="53" subjects_affected="53" subjects_at_risk="424"/>
                <counts group_id="E3" events="55" subjects_affected="49" subjects_at_risk="427"/>
                <counts group_id="E4" events="41" subjects_affected="40" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="427"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="63" subjects_affected="63" subjects_at_risk="420"/>
                <counts group_id="E2" events="62" subjects_affected="62" subjects_at_risk="424"/>
                <counts group_id="E3" events="63" subjects_affected="58" subjects_at_risk="427"/>
                <counts group_id="E4" events="68" subjects_affected="65" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="177" subjects_affected="168" subjects_at_risk="420"/>
                <counts group_id="E2" events="164" subjects_affected="155" subjects_at_risk="424"/>
                <counts group_id="E3" events="200" subjects_affected="178" subjects_at_risk="427"/>
                <counts group_id="E4" events="188" subjects_affected="162" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bulimia nervosa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Polycystic ovaries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="427"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Hand dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="427"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="427"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

